HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Etiology and outcome of hydrops fetalis: report of 62 cases.

AbstractAIM:
We aimed to define the etiologic and prognostic factors in live-born infants with hydrops fetalis (HF) in our tertiary neonatal intensive care unit over a 10-year period.
METHODS:
Medical records of newborn infants with HF during 2002-2011 were reviewed retrospectively. Demographic data, prenatal interventions, clinical and laboratory findings, outcomes, and the results of postmortem examinations were analyzed.
RESULTS:
During the study period, 62 newborn infants with HF were identified from 16,200 live-born deliveries and the incidence of HF was 3.8/1000 live births in our hospital. Twenty-eight infants (45.2%) had immune HF, whereas 34 (54.8%) had nonimmune HF. An etiologic factor could be identified in 24 (70.5%) infants with nonimmune HF. Lymphatic dysplasias comprised the majority (23.5%) of the infants with nonimmune HF. Mortality rate was 50%. The presence of two or more serous cavity effusions and gestational age were independently associated with the risk of mortality.
CONCLUSION:
Despite the improvements in neonatal care, mortality rate in infants with HF is still high. Gestational age and the extent of serous cavity determine the risk of mortality. Timely and advanced prenatal or postnatal new therapeutic strategies may alter this fatal outcome in appropriate patients.
AuthorsSahin Takci, Mina Gharibzadeh, Murat Yurdakok, Ozgur Ozyuncu, Ayse Korkmaz, Zuhal Akcoren, Sule Yigit
JournalPediatrics and neonatology (Pediatr Neonatol) Vol. 55 Issue 2 Pg. 108-13 (Apr 2014) ISSN: 2212-1692 [Electronic] Singapore
PMID24094760 (Publication Type: Journal Article)
CopyrightCopyright © 2013. Published by Elsevier B.V.
Topics
  • Female
  • Gestational Age
  • Humans
  • Hydrops Fetalis (etiology, mortality)
  • Infant, Newborn
  • Male
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: